Restricted accessResearch articleFirst published online 2025-09
Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa
Mutations leading to premature termination codons in COL7A1 are commonly associated with severe generalized recessive dystrophic epidermolysis bullosa (RDEB). Previous research, including our own, has indicated that removing mutated COL7A1 exons along with the consequent reframing of COL7A1 may not pose noticeable impact on protein function, offering a potential therapeutic strategy. However, investigations into the long-term in vivo effects of genome editing-mediated removal of mutant exons have only focused on the small exon 80 thus far. Hence, this study focuses on exons 73 and 105 of COL7A1 to explore whether targeted exon removal, through a CRISPR/Cas9-assisted, Non-homologous end joining (NHEJ)-mediated approach, could be extended to other larger exons. Introducing ribonucleoprotein complexes carrying Cas9 and optimized sgRNA guide pairs for each exon (73 and 105) through electroporation efficiently led to their removal, consequently restoring type VII collagen (C7) synthesis in RDEB primary patient cells carrying frameshift mutations in these exons. In vitro tests indicated the normal stability of the resulting C7 variants expressed at physiological levels, while in vivo analyses of regenerated skin grafted onto immunodeficient mice using E73 or E105 RDEB edited cells demonstrated the proper deposition of C7 at the basement membrane zone, thereby restoring normal dermo-epidermal adherence. This study enhances the broader potential of the exon deletion approach in the treatment of RDEB.
HovnanianA, DuquesnoyP, Blanchet-BardonC, et al.Genetic linkage of recessive dystrophic epidermolysis bullosa to the type VII collagen gene. J Clin Invest, 1992; 90(3):1032–1036; doi: 10.1172/jci115916
5.
ChristianoAM, HoffmanGG, Chung-HonetLC, et al.Structural organization of the human type VII Collagen Gene (COL7A1), composed of more exons than any previously characterized gene. Genomics, 1994; 21(1):169–179; doi: 10.1006/GENO.1994.1239
6.
TurczynskiS, TiteuxM, TonassoL, et al.Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model. J Invest Dermatol, 2016; 136(12):2387–2395; doi: 10.1016/J.JID.2016.07.029
7.
BremerJ, BornertO, NyströmA, et al.Antisense Oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis Bullosa. Mol Ther Nucleic Acids, 2016; 5(10):e379; doi: 10.1038/MTNA.2016.87
8.
BornertO, KühlT, BremerJ, et al.Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy. Mol Ther, 2016; 24(7):1302–1311; doi: 10.1038/MT.2016.92
9.
BornertO, HogervorstM, NauroyP, et al.QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: A preclinical study. J Invest Dermatol, 2021; 141(4):883–893.e6; doi: 10.1016/J.JID.2020.08.018
10.
VermeerFC, BremerJ, SietsmaRJ, et al.Therapeutic prospects of exon skipping for epidermolysis bullosa. Int J Mol Sci, 2021; 22(22):12222; doi: 10.3390/IJMS222212222
11.
Du RandA, HuntJ, SamsonC, et al.Highly efficient CRISPR/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa. Bioeng Transl Med, 2024; 9(4):e10640; doi: 10.1002/BTM2.10640
12.
MencíaÁ, ChamorroC, BonafontJ, et al.Deletion of a pathogenic mutation-containing exon of COL7A1 allows clonal gene editing correction of RDEB patient epidermal stem cells. Mol Ther Nucleic Acids, 2018; 11:68–78; doi: 10.1016/j.omtn.2018.01.009
13.
BonafontJ, MencíaÁ, GarcíaM, et al.Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-Mediated gene editing. Mol Ther, 2019; 27(5):986–998; doi: 10.1016/J.YMTHE.2019.03.007
14.
HovnanianA, RochatA, BodemerC, et al.Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation. Am J Hum Genet, 1997; 61(3):599–610; doi: 10.1086/515495
15.
EscámezMJ, GarcíaM, Cuadrado-CorralesN, et al.The first COL7A1 mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation. Br J Dermatol, 2010; 163(1):155–161; doi: 10.1111/J.1365-2133.2010.09713.X
16.
RodríguezFA, GanaMJ, YuberoMJ, et al.Novel and recurrent COL7A1 mutations in Chilean patients with dystrophic epidermolysis bullosa. J Dermatol Sci, 2012; 65(2):149–152; doi: 10.1016/J.JDERMSCI.2011.11.010
17.
NataleMI, ManzurGB, LussoSB, et al.Analysis of COL7A1 pathogenic variants in a large cohort of dystrophic epidermolysis bullosa patients from Argentina reveals a new genotype–phenotype correlation. Am J Med Genet A, 2022; 188(11):3153–3161; doi: 10.1002/AJMG.A.62957
18.
WarshauerEM, BrownA, FuentesI, et al.Ancestral patterns of recessive dystrophic epidermolysis bullosa mutations in Hispanic populations suggest Sephardic ancestry. Am J Med Genet A, 2021; 185(11):3390–3400; doi: 10.1002/AJMG.A.62456
19.
MecklenbeckS, Hammami-HauasliN, HopfnerB, et al.Clustering of COL7A1 mutations in exon 73: Implications for mutation analysis in dystrophic epidermolysis bullosa. J Invest Dermatol, 1999; 112(3):398–400; doi: 10.1046/J.1523-1747.1999.00518.X
20.
Van den AkkerPC, JonkmanMF, RengawT, et al.The international dystrophic epidermolysis bullosa patient registry: An online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat, 2011; 32(10):1100–1107; doi: 10.1002/HUMU.21551
Di NunzioF, MaruggiG, FerrariS, et al.Correction of Laminin-5 Deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. Mol Ther, 2008; 16(12):1977–1985; doi: 10.1038/MT.2008.204
23.
FernándezA, MorínM, Muñoz-SantosD, et al.Simple protocol for generating and genotyping genome-edited mice with CRISPR-Cas9 reagents. Curr Protoc Mouse Biol, 2020; 10(1):e69; doi: 10.1002/CPMO.69
24.
CerveraST, Rodríguez-MartínC, Fernández-TabaneraE, et al.Therapeutic potential of ewsr1–fli1 inactivation by crispr/cas9 in Ewing sarcoma. Cancers (Basel), 2021; 13(15):3783; doi: 10.3390/CANCERS13153783
25.
López-MárquezA, MorínM, Fernández-PeñalverS, et al.CRISPR/Cas9-mediated allele-specific disruption of a dominant COL6A1 pathogenic variant improves collagen VI network in patient fibroblasts. Int J Mol Sci, 2022; 23(8):4410; doi: 10.3390/IJMS23084410
26.
Alonso-LermaB, JabaleraY, SamperioS, et al.Evolution of CRISPR-associated endonucleases as inferred from resurrected proteins. Nat Microbiol, 2023; 8(1):77–90; doi: 10.1038/S41564-022-01265-Y
27.
BornertO, KocherT, GretzmeierC, et al.Generation of rabbit polyclonal human and murine collagen VII monospecific antibodies: A useful tool for dystrophic epidermolysis bullosa therapy studies. Matrix Biol Plus, 2019; 4:100017; doi: 10.1016/J.MBPLUS.2019.100017
28.
GarcíaM, BonafontJ, Martínez-PalaciosJ, et al.Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors. Mol Ther Methods Clin Dev, 2022; 27:96–108; doi: 10.1016/j.omtm.2022.09.005
29.
HamKA, Aung-HtutMT, FletcherS, et al.Nonsequential splicing events alter antisense-mediated exon skipping outcome in COL7A1. Int J Mol Sci, 2020; 21(20):7705; doi: 10.3390/IJMS21207705
30.
HongSA, KimSE, LeeAY, et al.Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa. Mol Ther, 2022; 30(8):2664–2679; doi: 10.1016/J.YMTHE.2022.06.005
31.
ToyonagaE, NishieW, KomineM, et al.Skipped exon in COL7A1 determines the clinical phenotypes of dystrophic epidermolysis bullosa. Br J Dermatol, 2015; 172(4):1141–1144; doi: 10.1111/BJD.13386
32.
SheriffA, GuriI, ZebrowskaP, et al.ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation. Sci Rep, 2022; 12(1):19643; doi: 10.1038/s41598-022-24184-8
33.
NasoG, GkaziSA, GeorgiadisC, et al.Cytosine deaminase base editing to restore COL7A1 in dystrophic epidermolysis bullosa human: Murine skin model. JID Innov, 2023; 3(3):100191; doi: 10.1016/j.xjidi.2023.100191
34.
SteinbeckBJ, GaoXD, McElroyAN, et al.Twin prime editing mediated exon skipping/reinsertion for restored collagen VII expression in recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology, 2024; 144(12):2764–2777.e9; doi: 10.1016/j.jid.2024.04.013
35.
OsbornMJ, NewbyGA, McElroyAN, et al.Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. J Invest Dermatol, 2020; 140(2):338–347.e5; doi: 10.1016/j.jid.2019.07.701
36.
Guri-LamceI, AlrokhY, GrahamC, et al.Lipid nanoparticles efficiently deliver the base editor ABE8e for COL7A1 correction in dystrophic epidermolysis bullosa fibroblasts in vitro. J Invest Dermatol, 2024; 144(10):2314–2317.e3; doi: 10.1016/J.JID.2024.03.027
37.
WangX, WangX, LiY, et al.CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa. Mol Ther Methods Clin Dev, 2023; 31:101134; doi: 10.1016/J.OMTM.2023.101134
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
